Jilin Aodong Pharmaceutical Group Co., Ltd.

000623.SZ

000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. CN flag

Shenzhen

16.72

CNY

+0.45

(+2.77%)

1.63EPS

10.26P/E

18.85BMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE000000719

Return %

Stock

S&P500

11.02

12.29

16.52

46.86

9.50

106.19

Use logarithmic scale

Stock Chart Unavailable

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	1.24	1.68	1.93	2.01	2.38	2.56	2.86	2.66	1.94	2.02	2.53	3.06	2.22	2.02
Basic EPS, GAAP	0.55	0.91	1.22	2.23	1.45	1.6	0.8	1.21	1.48	1.56	1.57	1.3	1.32	1.64
Free Cash Flow per Basic Share	-0.05	-0.09	-0.1	0.05	0.15	0.15	0.09	0.14	0.14	0.01	0.13	-0.31	-0.18	-0.2
Dividend per Share	0.12	0.08	0.08	0.17	0.26	0.23	0.3	0.21	0.22	0.22	0.33	0.36	0.9	0.85
Book Value per Share	7.36	6.97	8.05	9.81	11.04	12.24	12.51	13.42	14.58	16	17.23	18.26	17.82	18.28
Tangible Book Value per Share	8.12	9.29	10.65	14.8	16.12	17.36	17.89	18.96	19.93	21.51	22.72	23.91	24.41	24.78
Basic Weighted Avg Shares	1,167	1,166	1,161	1,163	1,149	1,163	1,163	1,163	1,158	1,139	1,135	1,125	1,177	1,176
Sales/Revenue/Turnover	1,445	1,957	2,240	2,335	2,737	2,977	3,324	3,088	2,252	2,304	2,868	3,449	2,611	2,372
Operating Margin (%)	9.45	11.13	14.29	13.14	14.13	14.79	12.33	9.59	2.37	4.89	8.38	7.74	-2.65	-5.42
Depreciation Expense	83	95	107	135	161	179	187	194	195	204	226	234	235	- -
Net Income, GAAP	646	1,059	1,411	2,594	1,666	1,863	935	1,404	1,709	1,781	1,781	1,460	1,551	1,925
Effective Tax Rate (%)	4.79	10.8	4.54	2.56	4.84	4.55	6.5	5.84	1.46	- -	- -	3.72	0.15	2.3
Profit Margin (%)	44.72	54.11	62.97	111.09	60.89	62.6	28.13	45.45	75.89	77.29	62.09	42.33	59.43	81.14
Working Capital	1,450	1,895	2,178	1,282	2,157	2,107	5,143	5,322	4,782	4,870	3,767	1,277	2,369	2,249
LT Debt	- -	- -	22	22	- -	- -	1,910	2,006	2,144	2,235	2,321	21	1,012	1,011
Total Equity	9,753	11,100	12,659	17,584	18,874	20,514	21,244	22,445	23,529	25,039	26,338	27,500	29,282	29,680
Return on Invested Capital (%)	1.38	1.86	2.56	1.91	1.95	2.12	1.75	1.17	0.21	- -	- -	0.86	-0.22	-0.4
Return on Capital (%)	7.63	12.5	15.89	23.57	13.26	13.69	6.58	8.77	9.88	- -	- -	6.91	7.07	8.53
Return on Common Equity (%)	7.75	12.66	16.15	25	13.83	13.85	6.5	9.31	10.52	10.14	9.42	7.28	7.47	9.11

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	3.05%	-0.87%	-24.31%
Net Income, GAAP	7.44%	2.84%	6.27%
Free Cash Flow	85.56%	153.27%	-38.97%
Total Cash Common Dividend	38.43%	44.9%	164.62%
Total Equity	9.15%	5.47%	6.48%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Ms. Shuqin Guo
Full Time Employees: 5,745
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 2158 Aodong Street Dunhua People's Republic of China 133700
IPO Date: Oct 28, 1996
Website: jlaod.com
Similar Companies: Pak Fah Yeow International Limited (0239.HK)
Amrutanjan Health Care Limited (AMRUTANJAN.BO)
Suven Life Sciences Limited (SUVEN.BO)
Bafna Pharmaceuticals Limited (BAFNAPH.NS)
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
Univec, Inc. (UNVC)
Business: Jilin Aodong Pharmaceutical Group Co., Ltd. produces and sells pharmaceutical products in China. The company offers various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It also engages in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; packaging design and printing activities; production and sale of medicinal packaging materials; and information consulting and advertising design activities. The company was founded in 1957 and is headquartered in Dunhua, China.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	1.24	1.68	1.93	2.01	2.38	2.56	2.86	2.66	1.94	2.02	2.53	3.06	2.22	2.02
Basic EPS, GAAP	0.55	0.91	1.22	2.23	1.45	1.6	0.8	1.21	1.48	1.56	1.57	1.3	1.32	1.64
Free Cash Flow per Basic Share	-0.05	-0.09	-0.1	0.05	0.15	0.15	0.09	0.14	0.14	0.01	0.13	-0.31	-0.18	-0.2
Dividend per Share	0.12	0.08	0.08	0.17	0.26	0.23	0.3	0.21	0.22	0.22	0.33	0.36	0.9	0.85
Book Value per Share	7.36	6.97	8.05	9.81	11.04	12.24	12.51	13.42	14.58	16	17.23	18.26	17.82	18.28
Tangible Book Value per Share	8.12	9.29	10.65	14.8	16.12	17.36	17.89	18.96	19.93	21.51	22.72	23.91	24.41	24.78
Basic Weighted Avg Shares	1,167	1,166	1,161	1,163	1,149	1,163	1,163	1,163	1,158	1,139	1,135	1,125	1,177	1,176
Sales/Revenue/Turnover	1,445	1,957	2,240	2,335	2,737	2,977	3,324	3,088	2,252	2,304	2,868	3,449	2,611	2,372
Operating Margin (%)	9.45	11.13	14.29	13.14	14.13	14.79	12.33	9.59	2.37	4.89	8.38	7.74	-2.65	-5.42
Depreciation Expense	83	95	107	135	161	179	187	194	195	204	226	234	235	- -
Net Income, GAAP	646	1,059	1,411	2,594	1,666	1,863	935	1,404	1,709	1,781	1,781	1,460	1,551	1,925
Effective Tax Rate (%)	4.79	10.8	4.54	2.56	4.84	4.55	6.5	5.84	1.46	- -	- -	3.72	0.15	2.3
Profit Margin (%)	44.72	54.11	62.97	111.09	60.89	62.6	28.13	45.45	75.89	77.29	62.09	42.33	59.43	81.14
Working Capital	1,450	1,895	2,178	1,282	2,157	2,107	5,143	5,322	4,782	4,870	3,767	1,277	2,369	2,249
LT Debt	- -	- -	22	22	- -	- -	1,910	2,006	2,144	2,235	2,321	21	1,012	1,011
Total Equity	9,753	11,100	12,659	17,584	18,874	20,514	21,244	22,445	23,529	25,039	26,338	27,500	29,282	29,680
Return on Invested Capital (%)	1.38	1.86	2.56	1.91	1.95	2.12	1.75	1.17	0.21	- -	- -	0.86	-0.22	-0.4
Return on Capital (%)	7.63	12.5	15.89	23.57	13.26	13.69	6.58	8.77	9.88	- -	- -	6.91	7.07	8.53
Return on Common Equity (%)	7.75	12.66	16.15	25	13.83	13.85	6.5	9.31	10.52	10.14	9.42	7.28	7.47	9.11

	Sep'24	Dec'24	Mar'25
ST Debt	1,160	1,277	1,367
LT Borrowings	995	995	996
LT Finance Leases	23	17	15
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	1,196	1,196	1,196
Market Capitalization	19,283	19,429	19,352

	Sep'24	Dec'24	Mar'25
Total Current Assets	5,293	4,833	4,831
Accounts Receivable, Net	971	787	933
Cash, Cash Equivalents & STI	2,967	2,675	2,650
Inventories	1,007	937	893
Total Current Liabilities	2,358	2,464	2,582
Payables & Accruals	- -	- -	- -
ST Debt	1,160	1,277	1,367
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	788	795	771	1,095	3,449
2024	861	550	498	701	2,611
2025	623	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	0.04	- -	- -	- -	0.36
2024	0.06	- -	- -	- -	0.9
2025	0.01	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	0.43	- -	- -	- -	1.3
2024	0.13	- -	- -	- -	1.32
2025	0.44	- -	- -	- -	- -

Jilin Aodong Pharmaceutical Group Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year